Janae Dudgeon, MD
Family Medicine · Syracuse, NENPI 1932514247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations.
Across 115 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$285
- Amgen$254
- Lilly USA, LLC$160
- Pfizer$108
- AstraZeneca$101
- AbbVie$90
- plus $824 from 28 others
What the payments were for
- Food & beverage$1,822100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $285 |
| Amgen | 17 | $254 |
| Lilly USA, LLC | 11 | $160 |
| Pfizer | 7 | $108 |
| AstraZeneca | 6 | $101 |
| AbbVie(2 entities) | 5 | $90 |
| Boehringer Ingelheim | 6 | $87 |
| Johnson & Johnson | 4 | $83 |
| Bayer | 6 | $80 |
| Ultragenyx Pharmaceutical Inc. | 4 | $66 |
| GSK | 3 | $43 |
| Philips North America LLC | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Viatris Specialty LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Biogen | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,822 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $153,567 |
| OzempicSemaglutide | 116 | $140,724 |
| JardianceEmpagliflozin | 114 | $113,773 |
| MounjaroTirzepatide | 69 | $78,492 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $59,472 |
| XareltoRivaroxaban | 36 | $30,809 |
| MyrbetriqMirabegron | 58 | $30,188 |
| ProliaDenosumab | 16 | $28,430 |
| TrulicityDulaglutide | 15 | $26,057 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 117 | $15,255 |
| LinzessLinaclotide | 27 | $14,989 |
| JanuviaSitagliptin Phosphate | 22 | $14,429 |
| RybelsusSemaglutide | 15 | $14,205 |
| KerendiaFinerenone | 20 | $12,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $285 | $154,928131 claims |
| PfizerEliquis | $108 | $153,567237 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $87 | $120,431128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $160 | $104,54984 claims |
| GSKTrelegy Ellipta | $43 | $59,47276 claims |
| Johnson & JohnsonXarelto | $83 | $30,80936 claims |
| AmgenProlia | $254 | $28,43016 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $101 | $20,08339 claims |
| AbbVieLinzess | $90 | $14,98927 claims |
| BayerKerendia | $80 | $12,88320 claims |
| Sanofi-aventis U.S. LLCLantus | $32 | $2,52529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Syracuse
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.